Korea South
Celltrion Inc, operating under the slogan "Built on Trust, Toward Innovation", is a pioneering entity in the biotechnology and pharmaceutical industries. Founded in 2002 and headquartered in Korea South, the company is distinguished for its comprehensive biopharmaceutical capabilities that span from research and development to distribution.
Specializing in monoclonal antibody (mAb) biosimilars, Celltrion is dedicated to addressing unmet medical needs with advanced, antibody-based biologics. The company boasts a robust business model that prioritizes efficiency, quality, and innovation, ensuring widespread access to life-changing therapies.
Their recent financial milestone includes securing a substantial $720.00M in Post IPO Equity investment on 01 July 2025. This funding is expected to support their commitment to advancing medical treatments and enhancing patient care on a global scale. Celltrion exemplifies a strategic partner, co-creating value throughout the healthcare journey.
